EGFR-IN-32 is a potent EGFR inhibitor with potential for investigating EGFR mutation-related diseases, particularly non-small cell lung cancer (NSCLC), as EGFR overexpression and mutations are strongly associated with uncontrolled cell proliferation and cancer progression.